New outstanding AB-KOLICARE™ clinical data published in Frontiers

9 September  2021 – 2 min read

Frontiers has published the latest clinical data of AB-KOLICARE™, that shows quite promising results on infant colic. This probiotic formulation leads AB-BIOTICS pediatric line, containing two bacteria strains with a battery of benefits for babies.

The randomized, double-blind, placebo-controlled clinical trial was conducted in 112 exclusively breastfed or mixed fed infants. It found that supplementation with AB-KOLICARE™ for 21 days resulted in shorter crying and/or fussing time and less episodes of crying and/or fussing compared to the placebo group. Of note, although both groups showed a response, infants receiving the probiotic solution displayed a clinically significant response in the first week compared to babies in the control group (83% vs 36%), and despite babies in both groups improving over time, probiotic treatment offered superior results on day 21. In addition, the probiotic formula improved fecal consistency. It was therefore concluded that AB-KOLICARE is an effective solution for the prevention and treatment of infant colic.

This new clinical results elevate AB-KOLICARE™ scientific status, and show how beneficial the product can be for babies and parents.

The two bacteria strains found in the probiotic formulation are quite unique; both are present in healthy infants, and one is a Human Residential Bifidobacteria (HRB), a Bifidobacteria found in healthy babies.

As explains Jordi Riera, Chief Business Development Officer, AB-Biotics:

“Emerging research shows that babies with infant colic have a different microbiota composition than those without. For instance, the presence of Bifidobacterium – beneficial bacteria that digest dietary fiber, help to prevent infection, and produce vitamins – is just 0.3% in colic babies, compared to 10% in non-colic infants. This suggests that gut microbiota may play an important role in the development of the condition and explains why probiotics are being explored as a potential treatment due to their gut-strengthening properties. In this study, the probiotic solution contained a strain of B. longum, which is a Human Resident Bifidobacteria (HRB) and one of the most common Bifidobacteria in healthy infants. This is significant since most other probiotic solutions for infants contain non-HRB such as B. animalis.”

This exciting news have been shared in a press release for specialised media. You can read the complete press release below, in english, french or italian:

Press release - ENG

Press release - FR

Press release - IT

Authors: Claudia Prat (Human Biologist)